T. Rowe Price Associates
IPSC icon

T. Rowe Price Associates’s Century Therapeutics IPSC Stock Holding History

T. Rowe Price Associates’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-14,882
Closed -$8K – 3100
2025
Q1 		$8K Hold
14,882
– – ﹤0.01% 3026
2024
Q4 		$16K Hold
14,882
– – ﹤0.01% 2998
2024
Q3 		$26K Hold
14,882
– – ﹤0.01% 2976
2024
Q2 		$38K Buy
+14,882
New +$47K ﹤0.01% 2882

Other funds holding IPSC

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates's IPSC Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Century Therapeutics (IPSC) in Q2 2025, closing a stake of 14,882 shares — an estimated $8K sold.

T. Rowe Price Associates first reported a position in IPSC in Q2 2024 and held it in 4 quarters. The position peaked at $38K in Q2 2024. 65 funds tracked by Wall St. Rank hold IPSC as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Century Therapeutics position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 14,882 Century Therapeutics shares in Q2 2025, an estimated $8K.
  • T. Rowe Price Associates first reported a position in Century Therapeutics in Q2 2024 and held it in 4 quarters.
  • T. Rowe Price Associates's Century Therapeutics position peaked at $38K in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.